2,504 research outputs found
Controlling the quantum computational speed
The speed of quantum computation is investigated through the time evolution
of the speed of the orthogonality. The external field components for classical
treatment beside the detuning and the coupling parameters for quantum treatment
play important roles on the computational speed. It has been shown that the
number of photons has no significant effect on the speed of computation.
However, it is very sensitive to the variation in both detuning and the
interaction coupling parameters.Comment: 9 pages, 10 figure
Associated Matrix Polynomials with the Second Kind Chebyshev Matrix Polynomials
This paper deals with the study of the associated Chebyshev matrix polynomials. Associated matrix polynomials with the Chebyshev matrix polynomials are defined here. Some properties of the associated Chebyshev matrix polynomials are obtained here. Further, we prove that the associated Chebyshev matrix polynomials satisfy a matrix differential equation of the second order
On Hermite-Hermite matrix polynomials
summary:In this paper the definition of Hermite-Hermite matrix polynomials is introduced starting from the Hermite matrix polynomials. An explicit representation, a matrix recurrence relation for the Hermite-Hermite matrix polynomials are given and differential equations satisfied by them is presented. A new expansion of the matrix exponential for a wide class of matrices in terms of Hermite-Hermite matrix polynomials is proposed
Quantum dense coding over Bloch channels
Dynamics of coded information over Bloch channels is investigated for
different values of the channel's parameters. We show that, the suppressing of
the travelling coded information over Bloch channel can be increased by
decreasing the equilibrium absolute value of information carrier and
consequently decreasing the distilled information by eavesdropper. The amount
of decoded information can be improved by increasing the equilibrium values of
the two qubits and decreasing the ratio between longitudinal and transverse
relaxation times. The robustness of coded information in maximum and partial
entangled states is discussed. It is shown that the maximum entangled states
are more robust than the partial entangled state over this type of channels
Asymmetrical <em>N</em><sup>4</sup>,<em>N</em><sup>9</sup>-Diacyl Spermines: SAR Studies of Nonviral Lipopolyamine Vectors for Efficient siRNA Delivery with Silencing of EGFP Reporter Gene
A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain.
BACKGROUND: Chronic cyclic pelvic pain (CCPP) affects women's quality of life and pituitary downregulation is often used for symptomatic relief. However, prolonged suppression of ovarian function is associated with menopausal side effects and can lead to osteoporosis. Currently, the use of gonadotropin releasing hormone agonists (GnRHa) for treatment of CCPP is usually restricted to 6-9 months, limiting their efficacy. There is limited information regarding safety and efficacy with longer-term use. The aim of this study is to examine the safety and efficacy of long-term (24 months) pituitary down-regulation with the GnRHa (Triptorelin SR) with add-back therapy (ABT) using Tibolone for symptom relief in women with CCPP. METHODS: A single-arm, prospective clinical trial at a Tertiary University Teaching Hospital of 27 patients receiving Triptorelin SR (11.25 mg) and Tibolone (2.5 mg). Outcomes measures were the safety of treatment assessed by clinical examination, haematological markers, liver and renal function tests and bone mineral density (BMD) at 12, 18 and 24 months as well as at 6 months post-treatment. Pain and health-related quality of life (HR-QoL) assessed using the endometriosis health profile (EHP-30) and chronic pain grade (CPG) questionnaires. RESULTS: There was no evidence for any significant harmful effects on any of the measured haematological, renal or liver function tests. Although results regarding the effect on BMD are not conclusive there is an increased risk of development of osteopaenia after 12 months of treatment. Pain and HRQoL assessments showed significant improvement during medication, but with deterioration after treatment cessation. CONCLUSION: Long- term Triptorelin plus Tibolone add-back therapy in women suffering from CCPP does not appear to be associated with significant serious adverse events apart from the possibility of deterioration in the BMD that needs to be monitored. This mode of therapy appears to be effective in pain relief and in improving quality of life over a 24-month period. TRIAL REGISTRATION: Clinical trials database NCT00735852
- …